Corporate Reputation of Pharma in 2020 During the COVID-19 Pandemic – Respiratory Edition: Boehringer Ingelheim, Pfizer, Janssen and Roche/Genentech Get “Best” Votes within Patient Group – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “The Corporate Reputation of Pharma in 2020 During the COVID-19 Pandemic – The Patient Perspective – Respiratory Edition – The Views of 116 Respiratory Conditions Patient Groups” report has been added to ResearchAndMarkets.com’s offering.

The results of an independent survey of 116 respiratory patient groups in 2020. Collectively, these patient groups reached out to 66,200 patients with various respiratory conditions during 2020. The respondent respiratory patient groups commented on 17 companies, selecting those with the “Best” corporate reputation in 2020, and assessing which were “Best” at tackling Covid-19 during 2020.

When? The survey was conducted in November 2020-February 2021, when key events of the pandemic will have influenced the opinions of respondent respiratory patient groups.

The questionnaire? Pharma was assessed across a wide range of its activities important to patients and patient groups, including a new indicator for 2020 – pharma’s effectiveness at tackling Covid-19 during that year.

How were the companies assessed? The indicators used to measure a company’s corporate reputation: 1. Covid-19 response [new for the 2020 survey] 2. Patient centricity 3. Patient information 4. Patient safety 5. High-quality products 6.i. Transparency: pricing 6.ii. Transparency: clinical-trial data 6.iii. Transparency: funding of external stakeholders 7. Integrity 8. Quality of relationships with patient groups 9. Providing services ‘beyond the pill’ 10.i. Engaging patients in research 10.ii. Engaging patients in development.

SUMMARY OF FINDINGS

Patient groups responding to 2020’s ‘Corporate Reputation of Pharma’ survey are uniquely positioned to comment on the pharma industry’s performance during the pandemic, as patient organisations not only understand the perceptions of patients, but are also the only stakeholder to network with ALL other stakeholders in the healthcare system. For this reason, the analyst collected (November 2020 to February 2021) the opinions of 116 respiratory patient groups on the performance of the pharmaceutical industry during the Covid-19 pandemic of 2020.

Respiratory patient-group perspectives on pharma during the Covid-19 pandemic.

INDUSTRY-WIDE FINDINGS IN THE FIELD OF RESPIRATORY CONDITIONS, 2020

• The pharma industry’s effectiveness at tackling Covid-19, 2020. 60% of 2020’s respondent respiratory patient groups judged the industry’s actions in tackling Covid-19 to be “Very effective” or “Effective” during 2020 (similar to the 62% average from patient groups therapy-wide in 2020).
• The pharma industry’s corporate reputation, 2020. 53% of 2020’s respondent respiratory patient groups stated that the pharmaceutical industry had an “Excellent” or “Good” corporate reputation (around the same as the 56% reported by respiratory patient groups in 2019).

THE 2020 RANKINGS OF INDIVIDUAL PHARMA COMPANIES WORKING IN THE FIELD OF RESPIRATORY DISEASES

Two sets of rankings are provided in the 2020 analyses, from the perspective of the 116 respondent respiratory patient groups: (1.) assessing the corporate reputation of 17 pharma companies; and (2.) assessing the corporate reputation of just 12 of the largest pharma companies (‘big pharma’).

Response to Covid-19 in 2020, according to 116 respondent respiratory patient groups

1. Out of 17 pharma companies: The three pharma companies voted “Best” for supporting patients with respiratory conditions during the Covid-19 pandemic in 2020 were: 1st, Boehringer Ingelheim 2nd, Janssen and, 3rd, Pfizer – as assessed by respondent respiratory patient groups familiar with the company.

2. Out of 12 ‘big-pharma’ companies: The three ‘big-pharma’ companies voted “Best” in 2020 for supporting patients with respiratory conditions during the Covid-19 pandemic in 2020 were: 1st, Janssen 2nd, Pfizer and, 3rd, Roche/Genentech – as assessed by respondent respiratory patient groups familiar with the company.

Overall corporate reputation in 2020, according to 116 respondent respiratory patient groups

1. Out of 17 pharma companies: The three pharma companies voted “Best” for overall corporate reputation in 2020 were: 1st, Boehringer Ingelheim 2nd, Pfizer and, 3rd, Janssen – as assessed by respondent respiratory patient groups familiar with the company.

2. Out of 12 ‘big-pharma’ companies: The three ‘big-pharma’ companies voted “Best” in 2020 for overall corporate reputation in 2020 were: 1st, Pfizer 2nd, Janssen and, 3rd, Roche/Genentech. The commentaries supplied to the analyst by 2020’s respondent respiratory patient groups made clear that their opinions on pharma companies in 2020 were primarily influenced by company responses to Covid-19 -whether that be the development and production of vaccines, or other efforts by companies to support patients with respiratory conditions during lockdown.

Key Topics Covered:

1 Executive summary

11 Relationships that respiratory patient groups have with pharma

14 Industry-wide findings

20 The corporate-reputation rankings of 17 pharma companies, 2020 (v. 2019), as assessed by respiratory patient groups familiar with the companies

36 The corporate-reputation rankings of 9 pharma companies, 2020, as assessed by respiratory patient groups that work/partner with the companies

52 Profiles of the 17 companies, 2020 (v. 2019)

APPENDICES

I Profiles of respondent respiratory patient groups, 2020

II List of respondent respiratory patient groups that wished to be attributed, 2020

III What respondent respiratory patient groups say about pharma (and how the industry can improve), 2020/2021

TABLES AND CHARTS

CHARTS AND TABLES FOR EACH OF THE 17 COMPANIES

Companies Mentioned

• AbbVie
• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Bristol Myers Squibb
• Chiesi Farmaceutici
• Eli Lilly
• GSK
• Janssen
• Merck & Co/MSD
• Mylan
• Novartis
• Pfizer
• Roche/Genentech
• Sandoz
• Sanofi
• Teva

For more information about this report visit https://www.researchandmarkets.com/r/lbwxbs

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900